The impact of micronized progesterone on cardiovascular events – a systematic review

References

• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Rovinski D, Ramos RB, Fighera TM, et al. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and Meta-analysis. Thromb Res. 2018;168:83–95.
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe GD, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and Meta-analysis. BMJ. 2008;336(7655):1227–1231.
   PubMed Web of Science ®Google Scholar
• Olie V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17(5):457–463. Sep
   PubMed Web of Science ®Google Scholar
• The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017;24(7):728–753.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
   PubMed Web of Science ®Google Scholar
• Inwald EC, Albring C, Baum E, et al. Perimenopause and Postmenopause – Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3-Level, AWMF Registry Number 015-062, September 2020). Geburtshilfe Frauenheilkd. 2021;81(6):612–636. Jun
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10(1):39.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000.
   Google Scholar
• Lobo RA, Kaunitz AM, Santoro N, et al. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. Climacteric. 2019;22(6):610–616.
   PubMed Web of Science ®Google Scholar
• Xue W, Deng Y, Wang YF, et al. Effect of half-dose and standard-dose conjugated equine estrogens combined with natural progesterone or dydrogesterone on components of metabolic syndrome in healthy postmenopausal women: a randomized controlled trial. Chin Med J. 2016;129(23):2773–2779. Dec 5‐
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–1231.
   PubMed Web of Science ®Google Scholar
• Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke. 2016;47(7):1734–1741.
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–260.
   PubMed Web of Science ®Google Scholar
• Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18(5):488–493.
   PubMed Web of Science ®Google Scholar
• Perez-Lopez FR, Cuadros-Lopez JL, Fernandez-Alonso AM, et al. Assessing fatal cardiovascular disease risk with the SCORE (Systematic Coronary Risk Evaluation) scale in post-menopausal women 10 years after different hormone treatment regimens. Gynecol Endocrinol. 2010;26(7):533–538.
   PubMed Web of Science ®Google Scholar
• Mahmud K. Natural hormone therapy for menopause. Gynecol Endocrinol. 2010;26(2):81–85.
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. ATVB. 2010;30(2):340–345.
   Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women – impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
   PubMed Web of Science ®Google Scholar
• Whiteman MK, Cui Y, Flaws JA, et al. Low fibrinogen level: a predisposing factor for venous thromboembolic events with hormone replacement therapy. Am J Hematol. 1999;61(4):271–273.
   PubMed Web of Science ®Google Scholar
• Miller VT, Larosa J, Barnabei V, et al. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women – The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273(3):199–208. Jan
   PubMed Web of Science ®Google Scholar
• Miller VT, Byington RL, Espeland MA, et al. Baseline characteristics of the PEPI participants. Postmenopausal Estrogen/Progestin Interventions. Control Clin Trials. 1995;16(4 Suppl):54S–65S.
   PubMedGoogle Scholar
• Lobo R, Liu J, Kaunitz AM, et al. Effects of single-capsule 17β-estradiol/progesterone (TX-001HR) on metabolic parameters and cardiovascular outcomes in menopausal women of the replenish trial. Menopause. 2018;25(12):1484–1485.
   Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368.
   PubMed Web of Science ®Google Scholar
• Langer RD, Simon JA, Pines A, et al. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Climacteric. 2017;20(5):402–413. Oct
   PubMed Web of Science ®Google Scholar
• Coquoz A, Gruetter C, Stute P. Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review. Climacteric. 2019;22(2):148–114.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Tian W. The effects of progesterones on blood lipids in hormone replacement therapy. Lipids Health Dis. 2017;16(1):219.
   PubMedGoogle Scholar
• Hemelaar M, van der Mooren MJ, Rad M, et al. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril. 2008; 90(3):642–672.
   PubMed Web of Science ®Google Scholar
• Canonico M. Hormone therapy and hemostasis among postmenopausal women: a review. Menopause. 2014;21(7):753–762.
   PubMed Web of Science ®Google Scholar
• Canonico M, Alhenc-Gelas M, Plu-Bureau G, et al. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause. 2010;17(6):1122–1127.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Collins P, Mack WJ, et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012;15(3):217–228.
   PubMed Web of Science ®Google Scholar
• Tremollieres F, Brincat M, Erel CT, et al. EMAS position statement: managing menopausal women with a personal or family history of VTE. Maturitas. 2011;69(2):195–198.
   PubMed Web of Science ®Google Scholar